Financial Performance Overview
Natural Capsules Limited reported a consolidated net loss of ₹24.66 crore for FY26, a significant deterioration from the profit of ₹61.74 lakh in FY25. Despite this, revenue from operations grew 11% to ₹187.20 crore from ₹169.21 crore in the previous year. The standalone performance showed revenue of ₹173.77 crore with net profit of ₹11.16 crore, indicating the substantial drag from subsidiary operations.
Operational Challenges and Recovery
The company faced significant operational headwinds during the year, particularly a temporary shutdown of its Puducherry capsule facility from December 26, 2025 to January 29, 2026 due to licensing issues. This disruption affected production and dispatches, deferring approximately ₹6 crore of shipments. However, Q4 emerged as the strongest operating quarter with revenue of ₹58.45 crore following the resolution.
Subsidiary Performance and API Expansion
Natural Biogenex Private Limited, the API subsidiary, commenced commercial production at its Tumkur facility and produces complex steroidal APIs including Prednisolone, Betamethasone, and Dexamethasone under the Government's Production Linked Incentive scheme. The subsidiary reported substantial losses of ₹36.14 crore after tax on turnover of ₹13.43 crore. The company also signed a manufacturing agreement with FermBox Bio in Q4 and is pursuing international certifications including WHO GMP, USFDA, and EU GMP.
Financial Position and Costs
The company's financial position showed total assets of ₹424.16 crore with borrowings of ₹110.34 crore. Finance costs surged to ₹10.95 crore from ₹6.31 crore in FY25, while depreciation amounted to ₹17.14 crore on newly commissioned capacity. The debt-equity ratio increased to 80.71% from 63.07% in the previous year. Operating cash flow remained positive at ₹10.92 crore.
Corporate Governance and AGM Matters
The Board recommended no dividend for FY26 and will seek shareholder approval at the 33rd AGM on August 12, 2026 for several matters including reappointment of directors Jyoti Mundra and Laxminarayan Moondra, revision of remuneration for key management personnel, and approval of related party transactions with Natural Biogenex up to ₹50 crores.
Key Audit Matters and Contingencies
Auditors highlighted the valuation of trade receivables (₹71.35 crore with ₹6.44 crore allowance) and evaluation of uncertain tax positions as key audit matters. Contingent liabilities include bank guarantees of ₹74.41 crore and disputed tax demands of ₹0.83 crore under various appeals. The company also assessed the impact of the new Labour Code 2025 implementation.
Management Changes and Board Composition
Ms. Pranjal Deshmukh resigned as Company Secretary & Compliance Officer effective April 25, 2026, with Mr. Akshay Dutta appointed as successor effective May 27, 2026. The board composition includes Mr. Tekkar Yashwanth Prabhu as Chairman & Independent Director, along with managing director Sunil L. Mundra and other directors overseeing operations.